877131-21-0Relevant articles and documents
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Ma, Bin,Bohnert, Tonika,Otipoby, Kevin L.,Tien, Eric,Arefayene, Million,Bai, Judy,Bajrami, Bekim,Bame, Eris,Chan, Timothy R.,Humora, Michael,Macphee, J. Michael,Marcotte, Douglas,Mehta, Devangi,Metrick, Claire M.,Moniz, George,Polack, Evelyne,Poreci, Urjana,Prefontaine, Annick,Sheikh, Sarah,Schroeder, Patricia,Smirnakis, Karen,Zhang, Lei,Zheng, Fengmei,Hopkins, Brian T.
supporting information, p. 12526 - 12541 (2020/12/17)
Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti
PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS
-
Page/Page column 188, (2018/12/13)
The present invention relates to pyrimidine derivatives of formula (I) wherein (R1)n, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (II) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0216, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
